← Back to Search

Chemotherapy

Arm I: R-mabHD for Hodgkin's Lymphoma

Phase 2
Waitlist Available
Led By Prem A Nandiwada, M.D.
Research Sponsored by American Scitech International
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

120 subjects with Hodgkin's disease will be randomly divided into two groups: Group I receiving R-mabHD and Group II receiving a combination of Adriamycin,Bleomycin,Vinblastine and Dacarbazine. R-mabHD will be given once a week for eight weeks in a row. The ABVD combination will be given once every other week for 12 treatments. The hypothesis is that intervention with R-mabHD will lead to a quicker remission of Hodgkin's disease than the intervention with a combination of ABVD.

Eligible Conditions
  • Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Arm I: R-mabHDActive Control1 Intervention
Anti-hodgkin disease agent
Group II: Arm II: ABVDActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbIndustry Sponsor
2,682 Previous Clinical Trials
4,124,901 Total Patients Enrolled
American Scitech InternationalLead Sponsor
5 Previous Clinical Trials
2,690 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,669 Previous Clinical Trials
3,228,621 Total Patients Enrolled
~8 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top